LCTX — Lineage Cell Therapeutics, Inc.
—
NYSE ·
Health Care ·
Biotechnology ·
CIK 876343 ·
Last close
$0.82
Market Cap
$206.36M
52W High
$1.99
52W Low
$0.77
ADV30
1,982,730
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 1,434,000 | 1,429,000 | -7,314,000 | 4,232,000 | 100,110,000 | 26,499,000 | 34,167,000 |
| Jun 2026 | 1,069,000 | 1,069,000 | -8,923,000 | 1,482,000 | 106,220,000 | 37,355,000 | 46,422,000 |
| Mar 2026 | 1,725,000 | 1,725,000 | -7,593,000 | -4,812,000 | 109,533,000 | 35,939,000 | 56,838,000 |
| Dec 2025 | 6,608,000 | 6,542,000 | -6,548,000 | 851,000 | 112,584,000 | 40,791,000 | 69,238,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-23,816,000
Investing CF
$-13,712,000
Financing CF
$32,240,000
CapEx
$-574,000
Dividends Paid
—
Buybacks
$-41,000
EPS Diluted TTM
$-0.32
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-470,328,000
Inventory
—
Receivables
$790,000
ST Investments
$13,474,000
EBIT TTM
$-26,850,000
Pretax Income TTM
$-37,385,000
Interest Exp TTM
—
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$10,836,000
EBITDA
$-29,615,000
Free Cash Flow
$-15,393,250
Enterprise Value
$187,085,424
Total Cash
$45,176,000
Total Debt
$2,029,000
Shares Out
252,954,764
Trailing EPS
$-0.19
Book Value
$0.24
ROE
4.3%
ROA
-20.0%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 14,556,000 | -21,779,000 | -63,533,000 | 112,584,000 | 69,238,000 | 44,549,000 | -18,919,000 |
| Dec 2024 | 9,499,000 | -21,478,000 | -18,609,000 | 113,218,000 | 36,206,000 | 78,381,000 | -23,092,000 |
| Dec 2023 | 8,945,000 | -24,733,000 | -21,486,000 | 101,019,000 | 38,996,000 | 63,419,000 | -28,566,000 |
| Dec 2022 | 14,703,000 | -22,520,000 | -26,273,000 | 123,664,000 | 51,728,000 | 73,339,000 | 1,059,000 |
TTM Snapshot
Revenues TTM
$13,083,000
NetIncome TTM
$-32,260,000
OpCashFlow TTM
—
Assets (Latest)
$106,220,000
Forward EPS
$-0.14
Max Pain — expiry 2027-03-19
max pain strike: $1.00 · spot: $0.84 · call oi: 2,184 · put oi: 130
Expected Move to 2027-03-19:
±$2.00
(238.52%) —
implied range
$-1.16 –
$2.84
· ATM straddle on $1.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DTIL | PRECISION BIOSCIENCES INC | $196.95M | $7.05 | — |
| IKT | Inhibikase Therapeutics, Inc. | $193.57M | $1.38 | — |
| CABA | Cabaletta Bio, Inc. | $220.03M | $1.02 | — |
| CGEN | COMPUGEN LTD | $191.34M | $2.02 | — |
| ARTV | Artiva Biotherapeutics, Inc. | $190.81M | $3.86 | — |
News headlines (Yahoo Finance, 1h cache)
What Lineage Cell Therapeutics (LCTX) Said on Its Q3 Earnings Call
2026-11-13 08:14 · Yahoo
Lineage Cell: Q3 Earnings Snapshot
2026-11-12 21:20 · Yahoo
Lineage Cell Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-12 21:05 · Yahoo
Lineage Cell Therapeutics to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026
2026-11-05 13:00 · Yahoo
Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform
2026-09-08 12:00 · Yahoo
Lineage Cell Therapeutics (LCTX) Q2 2026 Earnings Call Transcript
2026-08-14 00:32 · Yahoo
Lineage Cell Therapeutics Q2 Earnings Call Highlights
2026-08-09 19:04 · Yahoo
Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026
2026-07-30 12:00 · Yahoo
Lineage Cell Therapeutics Maps COR1 Path With ‘Thaw and Inject’ Cell Therapy Plan
2026-07-14 07:02 · Yahoo
Lineage Cell Therapeutics (LCTX) Stock Faces Mixed Analyst Target Changes After Fresh Coverage
2026-06-18 16:20 · Yahoo
Recent Insider Activity
| Filed | Trade | Insider | Title | Type | Price | Qty | Value |
|---|---|---|---|---|---|---|---|
| 2026-11-17 8:45:04 | 2026-11-16 | Culley Brian M | Pres, CEO | P - Purchase | 0.92 | 40500 | 37098 |